Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
02325 YUNKANG GROUP
15.740-0.060-0.38%
Closed
02/08 16:08 CCT
High
15.900
Open
15.740
Turnover
3.10M
Low
15.700
Pre Close
15.800
Volume
196.00K
Price Forecast
News
Comment
Yunkang Group Limited's (HKG:2325) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Most readers would already be aware that Yunkang Group's (HKG:2325) stock increased significantly by 16% over the past three months. Given that the market rewards strong financials in the long-term,
Yunkang Group: Shares Pledged to Shanghai Pudong Development Bank
Yunkang Group: Shares Pledged to Shanghai Pudong Development Bank
Yunkang Group: Controlling Shareholder YK Development Has Pledged 181.1M Company Shares for a Loan Facility
Yunkang Group: Controlling Shareholder YK Development Has Pledged 181.1M Company Shares for a Loan Facility
Yunkang Group Limited's (HKG:2325) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
It is hard to get excited after looking at Yunkang Group's (HKG:2325) recent performance, when its stock has declined 24% over the past three months. However, stock prices are usually driven by a co
Yunkang Group: interim report 2022
Biden Signs Order to Curb China in Biotechnology Following Chip Bill
The US government is reported to introduce new regulations next month to prohibit American companies from exporting chipmaking equipment to Chinese factories that produce advanced semiconductors with sub-14 nanometer processes.
Yunkang Group: interim results announcement for the six months ended June 30, 2022
Yunkang Says Public Float 'Sufficient' after Hong Kong Regulator Warning
11:22 PM EDT, 08/01/2022 (MT Newswires) -- Hong Kong's securities regulator warned investors to "exercise extreme caution" when dealing in the shares of Yunkang Group (HKG:2325) as the company's high
Yunkang Group: date of board meeting
SFC: YUNKANG GROUP (02325.HK) Shareholding Highly Concentrated
The Securities and Futures Commission announced the high concentration of shareholding in YUNKANG GROUP (02325.HK). Findings suggested that, as at 8 July, 18 shareholders held an aggregate of about 14
Company Overview
More
Yunkang Group is a medical operation service provider in China. As early as 2008, Yunkang began providing standardized medical diagnosis services to medical institutions at all levels. Through the use of its professional diagnostic capabilities and medical consortium service network covering the whole country, Yunkang has gradually developed into a leading platform for medical operation services. Its testing programs have continued to increase, and it has carried out more than 2,000 testing programs and more than 50 million diagnostic tests in 2021.
As far as revenue in 2020 is concerned, as one of the top five companies in the Chinese medical operation service market, we have three major business lines, covering diagnostic testing services for medical consortia, diagnostic outsourcing services, and diagnostic testing services for non-medical institution customers. As of April 25, 2022, from the establishment of six operating modules and seven major technology platforms to six independent clinical laboratories covering key provinces and cities across the country, Yunkang has the largest number of first-class independent laboratories accredited by ISO15189 and CAP in the country, as well as more than 1,450 medical technicians. We have provided comprehensive, high-quality clinical diagnosis services to partner hospitals over a long period of time with accurate clinical diagnosis capabilities.
At the same time, Yunkang is also a leading medical consortium diagnostic service provider in China, providing a full range of medical and health services covering medical consortium diagnosis and diagnosis outsourcing. Yunkang provides diagnostic testing services to partner hospitals within the Chinese Medical Federation and assists them in improving their clinical diagnosis capabilities through on-site diagnostic centers. Up to now, Yunkang has successfully provided professional services to more than 700 medical institutions from more than 300 medical consortia across the country. As of December 31, 2021, the hospitals we have cooperated with are distributed in 31 provinces and cities in China, most of which are located in Guangdong Province, where our headquarters is located.
Over the past ten years, Yunkang has achieved sustainable growth through professional medical diagnostic services, strong standardization capabilities, innovative diagnostic and testing service business models for medical consortia, a large loyal customer base, and a visionary and experienced management team. Technology Yunkang, service health! Yunkang will continue to work to create a better and healthy life for all residents.
CEO： Yong Zhang
Market： Hong Kong motherboard
Listing Date： 05/18/2022
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet